Apyx Medical Q1 Earnings Call Highlights

2 hours ago 2

MarketBeat

Thu, May 7, 2026 astatine 8:22 AM CDT 7 min read

Apyx Medical logo

Key Points

Apyx reported Q1 gross of $12.5 million (up from $9.4M), driven by the commercialized ramp of the AYON body‑contouring strategy and a 36% summation successful Surgical Aesthetics to $10.7 million, and absorption raised full‑year 2026 gross guidance to $59–60 million (Surgical Aesthetics $54–55M).
The institution expects FDA 510(k) clearance for AYON powerfulness liposuction this quarter, which would adhd a halfway fat‑removal modality to the level and is expected to broaden adoption among surgeons who person paused until power‑assisted capableness is available.
Profitability and liquidity improved: gross borderline roseate to 63.5%, nett nonaccomplishment narrowed to $2.1 million (vs. $4.2M), adjusted EBITDA nonaccomplishment improved to $0.3 million, and currency totaled $31.1 million with absorption projecting currency runway done 2027.
Interested successful Apyx Medical Corporation? Here are 5 stocks we similar better.

Apyx Medical (NASDAQ:APYX) reported archetypal 4th 2026 gross of $12.5 million, up from $9.4 cardinal successful the prior-year period, driven chiefly by maturation successful its Surgical Aesthetics concern and continued momentum from the company’s AYON assemblage contouring system, which launched commercially successful September 2025.

AYON ramp and Surgical Aesthetics maturation

Chief Executive Officer Charlie Goodwin said archetypal 4th results reflected “continued beardown income ramp of our AYON assemblage contouring strategy successful the U.S., request for single-use handpieces worldwide, and summation successful Renuvion generator income internationally.” Surgical Aesthetics gross roseate 36% twelvemonth implicit twelvemonth to $10.7 million.

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

Goodwin noted the 4th marked the company’s “second afloat 4th of AYON income pursuing its afloat commercialized motorboat successful September 2025.” He added that portion request from Apyx’s existing lawsuit basal remained strong, the institution is besides seeing “a dependable summation successful engagement from caller accounts,” which helium attributed to rising marketplace consciousness and increasing assurance successful AYON’s capabilities. Goodwin said the institution continues to presumption adoption arsenic early-stage.

During the Q&A, Goodwin clarified that U.S. generator income declined successful portion owed to however the institution is present classifying transactions. When Apyx sells AYON systems, it counts them arsenic AYON income alternatively than generator sales, adjacent if the merchantability includes a generator constituent for a caller lawsuit oregon an upgrade to the Apyx One console. “We don’t seizure those generators separately,” helium said. “We number it each arsenic an AYON merchantability now.”

→ Tyson Foods' Total Returns: Tasty Treats for Income Investors?

Read Entire Article